ArticleMedicine2026
Comparative and diagnostic evaluation of maternal serum prostasin in early-onset preeclampsia.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We aimed to compare maternal serum prostasin levels between women with early-onset preeclampsia (PE) and healthy pregnant controls to establish pathophysiological differences. We also sought to evaluate the diagnostic performance of maternal serum prostasin as a potential biomarker for early-onset PE, including determination of optimal cutoff values for clinical application. This was a prospective case-control study including 43 pregnant women who were diagnosed with early-onset PE between 200/7 to 340/7 weeks of gestation from March to September 2022. Also, 45 healthy pregnant women were included in the control group. Demographic characteristics, complete blood count and biochemical parameters, and serum prostasin concentrations were documented. A receiver operating characteristic curve was generated to demonstrate the sensitivity and specificity of prostasin, and the optimal cutoff value was determined using the Youden index. The median maternal serum prostasin level was found to be significantly higher in the early-onset PE group (31.66 [27.12-51.00] ng/mL) compared to the control group (22.33 [16.03-25.89] ng/mL) with a P-value <.001. The area under the curve was found to be 0.820 ± 0.047 (95% CI: 0.729-0.912), indicating a statistically significant discriminative ability (P < .001). The optimal cutoff value for maternal serum prostasin level was determined using the Youden index, with a threshold of ≥26.44 ng/mL corresponding to a sensitivity of 0.837 and a specificity of 0.778 for the diagnosis of early-onset PE. Based on the multivariate model results, a maternal serum prostasin value of >26.44 ng/mL increases the risk of early-onset PE by approximately 20-fold. Maternal serum prostasin levels are significantly elevated in early-onset preeclamptic mothers compared to the healthy controls. These findings suggest that prostasin may play a role in early-onset PE pathophysiology and could serve as a biomarker for its diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.